<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01653301</url>
  </required_header>
  <id_info>
    <org_study_id>515(A1144)/2005</org_study_id>
    <nct_id>NCT01653301</nct_id>
  </id_info>
  <brief_title>Preoperative Downstaging of Extraperitoneal T3 Rectal Cancer: XELOXRT Versus XELACRT. A Multicenter, Phase III Study</brief_title>
  <acronym>INTERACT</acronym>
  <official_title>INTEnsification Radiotherapy With Accelerated Fractionation or ChemoTherapy And Local Excision After 3D External Radio-chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catholic University of the Sacred Heart</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catholic University of the Sacred Heart</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  INTERACT study: to evaluate the pathological response rate in cT3 rectal cancer&#xD;
&#xD;
        -  LEADER study: to evaluate the impact on local control of local excision&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  INTERACT study: to evaluate the pathological response rate evaluated according to TRG&#xD;
           scale comparing accelerated radiotherapy on the gross tumour combined plus standard&#xD;
           radiotherapy to the pelvis in association with chronomodulated capecitabine (XELACRT&#xD;
           arm) versus oxaliplatin added to standard pelvis radiotherapy and same chronomodulated&#xD;
           Capecitabine (XELOXRT arm)&#xD;
&#xD;
        -  LEADER study: to evaluate the impact on local control of local excision in patients who&#xD;
           had a major clinical response evaluated by MRI and confirmed by TRG 1-2 score.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2005</start_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological major downstaging</measure>
    <time_frame>15-20 weeks after the randomization</time_frame>
    <description>INTERACT study:&#xD;
evaluation of T pathological major downstaging, considered as the overall rate of any TRG1 or TRG 2 scored patients;&#xD;
LEADER study (optional):&#xD;
To evaluate the impact on local control of local excision in patients who had a major clinical response, evaluated by EUS/ MRI, yN0 evaluated by multislice CT / MRI, and confirmed by TRG 1-2 score.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor downstaging</measure>
    <time_frame>15-20 weeks after the randomization</time_frame>
    <description>Secondary objectives:&#xD;
Tumour downstaging, evaluated by the comparison of clinical staging before combined modality treatment toward pathological staging.&#xD;
feasibility of a sphincter saving surgical procedure;&#xD;
evaluation of activity of preoperative treatment (clinical response, facultative)&#xD;
post-surgical functional outcome;&#xD;
evaluation of the local control of the disease;&#xD;
estimates (Kaplan-Meier, product limit method) of the disease free survival;&#xD;
Evaluation of adverse events and adverse reactions to treatment, according to both the RTOG and NCI-CTC criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sphincter saving surgery</measure>
    <time_frame>15-20 weeks after the randomization</time_frame>
    <description>Secondary objectives:&#xD;
Tumour downstaging, evaluated by the comparison of clinical staging before combined modality treatment toward pathological staging.&#xD;
feasibility of a sphincter saving surgical procedure;&#xD;
evaluation of activity of preoperative treatment (clinical response, facultative)&#xD;
post-surgical functional outcome;&#xD;
evaluation of the local control of the disease;&#xD;
estimates (Kaplan-Meier, product limit method) of the disease free survival;&#xD;
Evaluation of adverse events and adverse reactions to treatment, according to both the RTOG and NCI-CTC criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>local control</measure>
    <time_frame>15-20 weeks after the randomization</time_frame>
    <description>Secondary objectives:&#xD;
Tumour downstaging, evaluated by the comparison of clinical staging before combined modality treatment toward pathological staging.&#xD;
feasibility of a sphincter saving surgical procedure;&#xD;
evaluation of activity of preoperative treatment (clinical response, facultative)&#xD;
post-surgical functional outcome;&#xD;
evaluation of the local control of the disease;&#xD;
estimates (Kaplan-Meier, product limit method) of the disease free survival;&#xD;
Evaluation of adverse events and adverse reactions to treatment, according to both the RTOG and NCI-CTC criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>survival</measure>
    <time_frame>15-20 weeks after the randomization</time_frame>
    <description>Secondary objectives:&#xD;
Tumour downstaging, evaluated by the comparison of clinical staging before combined modality treatment toward pathological staging.&#xD;
feasibility of a sphincter saving surgical procedure;&#xD;
evaluation of activity of preoperative treatment (clinical response, facultative)&#xD;
post-surgical functional outcome;&#xD;
evaluation of the local control of the disease;&#xD;
estimates (Kaplan-Meier, product limit method) of the disease free survival;&#xD;
Evaluation of adverse events and adverse reactions to treatment, according to both the RTOG and NCI-CTC criteria.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">616</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>XELOX-RT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Xeloda: 1300 mg/m2 chronomodulated (h 8.00 a.m. 25% of total dose ; h 6.00 p.m. 25% of total dose; h 11.00 p.m. 50% of total dose), during the whole treatment time;&#xD;
Oxaliplatin: 130mg/m2, days 1, 19, 38&#xD;
RT: pelvic treatment is the same for both arms: 45 Gy are delivered to the whole pelvis at 1.8 Gy daily, 5 times per week; In the XELOX-RT arm a boost of 5.4 Gy is delivered to the mesorectum corresponding to GTV, at 1.8 Gy daily, in 3 fractions, to a total dose of 50.4 Gy. The boost will be delivered at the end of the irradiation of the pelvis (sequential boost).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XELAC-RT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Xeloda 1650mg/m2 chronomodulated (h 8.00 a.m. 25% of total dose ; h 6.00 p.m. 25% of total dose; h 11.00 p.m. 50% of total dose) during the whole treatment time.&#xD;
RT: pelvic treatment is the same for both arms: 45 Gy are delivered to the whole pelvis at 1.8 Gy daily, 5 times per week.&#xD;
In the XEL-ACRT arm a boost of 10 Gy is delivered to the mesorectum corresponding to the GTV, at 1 Gy for fraction to a total dose of 55 Gy, in 10 fractions over 5 weeks, 2 times a week. The daily dose of the boost will be delivered twice a week immediately after the daily dose administered to the pelvis (concomitant boost).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XELAC RT</intervention_name>
    <description>Xeloda 1650mg/m2 chronomodulated (h 8.00 a.m. 25% of total dose ; h 6.00 p.m. 25% of total dose; h 11.00 p.m. 50% of total dose) during the whole treatment time.&#xD;
RT: pelvic treatment is the same for both arms: 45 Gy are delivered to the whole pelvis at 1.8 Gy daily, 5 times per week.&#xD;
In the XEL-ACRT arm a boost of 10 Gy is delivered to the mesorectum corresponding to the GTV, at 1 Gy for fraction to a total dose of 55 Gy, in 10 fractions over 5 weeks, 2 times a week. The daily dose of the boost will be delivered twice a week immediately after the daily dose administered to the pelvis (concomitant boost).</description>
    <arm_group_label>XELAC-RT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XELOX RT</intervention_name>
    <description>Xeloda: 1300 mg/m2 chronomodulated (h 8.00 a.m. 25% of total dose ; h 6.00 p.m. 25% of total dose; h 11.00 p.m. 50% of total dose), during the whole treatment time;&#xD;
Oxaliplatin: 130mg/m2, days 1, 19, 38&#xD;
RT: pelvic treatment is the same for both arms: 45 Gy are delivered to the whole pelvis at 1.8 Gy daily, 5 times per week; In the XELOX-RT arm a boost of 5.4 Gy is delivered to the mesorectum corresponding to GTV, at 1.8 Gy daily, in 3 fractions, to a total dose of 50.4 Gy. The boost will be delivered at the end of the irradiation of the pelvis (sequential boost).</description>
    <arm_group_label>XELOX-RT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INTERACT STUDY&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed primary adenocarcinoma of the rectum.&#xD;
&#xD;
          -  Tumour within 12 cm of the anal verge by proctoscopic examination or within 10 cm of&#xD;
             the anorectal ring by MRI.&#xD;
&#xD;
          -  Clinical stages (UICC 1997): cT2N0-2 low located tumour, cT3 N0-2.&#xD;
&#xD;
          -  Resectable disease at the routine examination.&#xD;
&#xD;
          -  Age &gt; 18 years.&#xD;
&#xD;
          -  Karnofsky Performance Status &gt; 60.&#xD;
&#xD;
          -  WBC &gt; 4,000 cells/ml, platelets &gt; 100,000 cells/ml.&#xD;
&#xD;
          -  Provision of written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of metastatic (M1) disease. If there were any suspicious findings (i.e. liver&#xD;
             metastasis, lung nodule, retroperitoneal adenopathy, etc.) the patient is to be&#xD;
             considered as ineligible, unless malignancy is ruled out by tissue documentation&#xD;
             (biopsy) before trial therapy is started.&#xD;
&#xD;
          -  Previous chemotherapy, immunotherapy, or radiation therapy to the pelvis.&#xD;
&#xD;
          -  Multiple primary cancers involving both the colon and rectum that would preclude a&#xD;
             patient from being classified as having only rectal cancer.&#xD;
&#xD;
          -  Incomplete healing from or other surgery.&#xD;
&#xD;
          -  Active inflammatory bowel disease.&#xD;
&#xD;
          -  Other co-existing malignancies or malignancies diagnosed within the last 5 years with&#xD;
             the exception of basal cell carcinoma or cervical cancer in situ.&#xD;
&#xD;
          -  Cardiovascular disease with a New York Heart Association Functional Status &gt; 2.&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &lt; 4 x 108/L or platelets &lt; 50 x 108/L.&#xD;
&#xD;
          -  Measured Creatinine clearance less than 65ml/min. (no drug dose reduction for lower&#xD;
             GFR is allowed).&#xD;
&#xD;
          -  ALT or AST &gt; 2.5 times the ULRR&#xD;
&#xD;
          -  Pregnancy or breastfeeding (women of child-bearing potential).&#xD;
&#xD;
          -  Any evidence of severe or uncontrolled systemic disease (e.g. unstable or&#xD;
             uncompensated respiratory, cardiac, hepatic or renal disease).&#xD;
&#xD;
          -  Any other significant clinical disorder or laboratory finding that makes it&#xD;
             undesirable for the patient to participate in the trial.&#xD;
&#xD;
        LEADER STUDY&#xD;
&#xD;
        Inclusion Criteria&#xD;
&#xD;
          -  Stage at the diagnosis: cT3N0. T3 patients at the diagnosis with 3 or less enlarged&#xD;
             nodes, evaluated by imaging, and without evidence of the same nodes after&#xD;
             radiochemotherapy, could be accrued according to Center decision, but will be analyzed&#xD;
             separately.&#xD;
&#xD;
          -  Patients with cT2N0, low located tumour, otherwise candidates to a Miles surgical&#xD;
             procedure, treated by neoadjuvant chemoradiation and with written consensus;&#xD;
&#xD;
          -  Major clinical response after chemoradiation, yT0-1N0; yT2N0 could be accrued&#xD;
             according to Center decision, but will be analyzed separately.&#xD;
&#xD;
          -  Circumferential extension less than 2 quarters;&#xD;
&#xD;
          -  Deep ulcer &lt; 2 cm of diameter;&#xD;
&#xD;
          -  Provision of written informed consent;&#xD;
&#xD;
          -  Biopsies are discouraged for the higher risk of following fistulae in irradiated&#xD;
             rectum;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pT3;&#xD;
&#xD;
          -  Positive margins;&#xD;
&#xD;
          -  TRG 3-5;&#xD;
&#xD;
          -  Major adverse features: lymphatic vessel invasion, vascular vessel invasion,&#xD;
             perineural invasion;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Vincenzo Valentini, MD</last_name>
    <phone>+390630155226</phone>
    <email>vvalentini@rm.unicatt.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Catholic University of Sacred Heart</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincenzo Valentini, MD</last_name>
      <phone>+390630155226</phone>
      <email>vvalentini@rm.unicatt.it</email>
    </contact>
    <investigator>
      <last_name>Vincenzo Valentini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>April 30, 2012</study_first_submitted>
  <study_first_submitted_qc>July 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2012</study_first_posted>
  <last_update_submitted>July 26, 2012</last_update_submitted>
  <last_update_submitted_qc>July 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Catholic University of the Sacred Heart</investigator_affiliation>
    <investigator_full_name>Vincenzo Valentini</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

